Takeda’ s Adcetris Wins “Landmark” Cancer Drugs Fund First In UK
Takeda’s Adcetris has received expanded recommendations from England’s health technology appraisal institute, NICE, following data collected through the Cancer Drugs Fund.
You may also be interested in...
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.
Innovators warn against slashing incentives and argue a lack of a common definition of unmet need is a stumbling block to proposals.